The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Phase 1/2 Active not recruiting 40 enrolled University of Kansas Medical Center

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment

Timeline

Start: 2022-03-22
Primary completion: 2025-11-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	—	Intravenous
Subject	Regorafenib	Small molecule	80 mg	Oral
Subject	Regorafenib	Small molecule	120 mg	Oral

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Summary

Timeline

Drugs

Indications